Search / Trial NCT00002236

A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients

Launched by PHARMACIA AND UPJOHN · Aug 30, 2001

Trial Information

Current as of November 03, 2024

Completed

Keywords

Drug Therapy, Combination Zidovudine Drug Administration Schedule Hiv Protease Inhibitors Cd4 Lymphocyte Count Indinavir Delavirdine Reverse Transcriptase Inhibitors Anti Hiv Agents Viral Load

Description

Patients are divided into 2 treatment groups; the groups are balanced with respect to viral load. Group A receives ZDV, DLV, and IDV 3 times daily. Group B receives ZDV, DLV, and IDV 2 times daily. Patients are evaluated for changes from baseline in viral load and CD4 cell count.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • You may be eligible for this study if you:
  • * Are HIV-positive.
  • * Have a viral load (level of HIV in the blood) of at least 20,000 copies/ml.
  • * Have a CD4 cell count of at least 50 cells/mm3.
  • * Are at least 14 years old (consent of parent or guardian is required if under 18).
  • Exclusion Criteria
  • You will not be eligible for this study if you:
  • * Have ever taken an anti-HIV drug other than ZDV.
  • * Have taken ZDV for more than 1 month.

About Pharmacia And Upjohn

Pharmacia and Upjohn, a global biopharmaceutical company, specializes in the research, development, and commercialization of innovative therapies that address unmet medical needs across multiple therapeutic areas. With a strong commitment to advancing healthcare, the company leverages cutting-edge science and technology to improve patient outcomes. Pharmacia and Upjohn is dedicated to conducting rigorous clinical trials that adhere to the highest ethical standards, ensuring the safety and efficacy of its products while fostering collaboration with healthcare professionals and regulatory authorities worldwide. Through its comprehensive portfolio, the company aims to enhance the quality of life for patients and contribute to the advancement of medical science.

Locations

Annandale, Virginia, United States

New York, New York, United States

Los Angeles, California, United States

Pittsburgh, Pennsylvania, United States

San Francisco, California, United States

Memphis, Tennessee, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials